A nurse is caring for a client who reports taking 0.5 oz of diphenhydramine elixir every night to sleep. The concentration on the client's bottle reads diphenhydramine 12.5 mg/5 mL. How many mg of diphenhydramine is the client taking each night? (Round the answer to the nearest tenth. Use a leading zero if it applies. Do not use a trailing zero.)

A. "I will take ibuprofen for mild pain": NSAIDs like ibuprofen can lead to sodium and fluid retention, which can exacerbate heart failure by increasing preload and worsening edema. They can also reduce the effectiveness of diuretics and ACE inhibitors, both of which are commonly used in heart failure management. Acetaminophen is generally preferred for pain relief as it does not contribute to fluid retention.

B. "I will weigh myself every other day": Daily weight monitoring is essential for detecting fluid retention early, as a sudden increase of 2–3 pounds in 24 hours or 5 pounds in a week can indicate worsening heart failure. Weighing every other day may delay the recognition of fluid overload, increasing the risk of complications such as pulmonary congestion and hospitalization.

C. "I will keep an exercise diary": Regularly tracking physical activity helps assess functional status and detect any decline in exercise tolerance, which could indicate worsening heart failure. An exercise diary allows the healthcare team to adjust activity levels appropriately, ensuring that the client remains active without overexertion. This approach also promotes adherence to a safe and structured exercise regimen, improving overall cardiovascular health.

D. "I will expect swelling in my feet and ankles": While mild peripheral edema can occur, it should never be considered normal in heart failure management. Swelling in the lower extremities suggests worsening fluid retention and should be promptly reported to the healthcare provider. Early intervention, such as medication adjustments or dietary modifications, can help prevent further decompensation and reduce the risk of hospitalization.

• Myocardial infarction: The rising troponin levels (Troponin T increasing from 0.08 ng/mL to 0.2 ng/mL and Troponin I rising from 0.01 ng/mL to 0.1 ng/mL) indicate myocardial injury. Persistent chest tightness, shortness of breath, diaphoresis, and anxiety suggest ongoing ischemia. The lack of complete pain relief after nitroglycerin further supports myocardial infarction rather than stable angina.
• Pulmonary embolism: Shortness of breath is a symptom of pulmonary embolism, but the absence of acute hypoxia, pleuritic chest pain, or significant coagulation abnormalities makes this less likely. The client's symptoms and laboratory findings more strongly support a cardiac etiology.
• Bleeding: While thrombolytic therapy increases bleeding risk, the aPTT (32 seconds) and platelet count (350,000/mm³) are within normal limits. There are no reported signs of active bleeding, such as hypotension, bruising, or hematuria, making this a less relevant immediate concern.
• Shortness of breath: Often present in myocardial infarction due to decreased cardiac output and pulmonary congestion. The combination of chest pain, diaphoresis, and dyspnea suggests worsening ischemia rather than a primary pulmonary process. However, it is a nonspecific symptom that can also indicate pulmonary embolism or respiratory distress.
• aPTT levels: Normal at 32 seconds (reference: 30–40 seconds), which suggests no immediate risk of abnormal clotting or excessive anticoagulation. This finding does not directly indicate myocardial infarction but is important in monitoring bleeding risk with thrombolytic therapy. A significantly elevated aPTT could raise concern for hemorrhagic complications.
• Elevated troponin levels: A highly specific marker for myocardial injury. The rise in Troponin T and Troponin I over time confirms myocardial damage, distinguishing acute coronary syndrome from stable angina. This trend is critical in diagnosing myocardial infarction, as troponin elevation correlates with the extent of cardiac muscle injury.